KR102789451B1 - 질산염 보강 조성물 및 이의 사용 방법 - Google Patents
질산염 보강 조성물 및 이의 사용 방법 Download PDFInfo
- Publication number
- KR102789451B1 KR102789451B1 KR1020217027218A KR20217027218A KR102789451B1 KR 102789451 B1 KR102789451 B1 KR 102789451B1 KR 1020217027218 A KR1020217027218 A KR 1020217027218A KR 20217027218 A KR20217027218 A KR 20217027218A KR 102789451 B1 KR102789451 B1 KR 102789451B1
- Authority
- KR
- South Korea
- Prior art keywords
- elemental
- composition
- nitrate
- magnesium
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title abstract description 12
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims abstract description 93
- 229910052751 metal Inorganic materials 0.000 claims abstract description 57
- 239000002184 metal Substances 0.000 claims abstract description 57
- 230000036772 blood pressure Effects 0.000 claims abstract description 45
- 230000001965 increasing effect Effects 0.000 claims abstract description 19
- 206010020772 Hypertension Diseases 0.000 claims abstract description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 48
- 239000011777 magnesium Substances 0.000 claims description 42
- 229910052749 magnesium Inorganic materials 0.000 claims description 38
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 29
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical group [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 claims description 19
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 17
- 229910052725 zinc Inorganic materials 0.000 claims description 17
- 239000011701 zinc Substances 0.000 claims description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- 239000013589 supplement Substances 0.000 claims description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 210000003205 muscle Anatomy 0.000 claims description 11
- 238000012549 training Methods 0.000 claims description 9
- 229910052742 iron Inorganic materials 0.000 claims description 8
- YSTODCCRDUZJQT-WCCKRBBISA-N nitric acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound O[N+]([O-])=O.OC(=O)[C@@H]1CCCN1 YSTODCCRDUZJQT-WCCKRBBISA-N 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 230000000153 supplemental effect Effects 0.000 claims 2
- 230000007103 stamina Effects 0.000 abstract description 4
- 239000002775 capsule Substances 0.000 description 46
- 229910002651 NO3 Inorganic materials 0.000 description 42
- 229940091250 magnesium supplement Drugs 0.000 description 42
- 229910001959 inorganic nitrate Inorganic materials 0.000 description 30
- MFUVDXOKPBAHMC-UHFFFAOYSA-N magnesium;dinitrate;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MFUVDXOKPBAHMC-UHFFFAOYSA-N 0.000 description 22
- 230000035488 systolic blood pressure Effects 0.000 description 20
- 230000007423 decrease Effects 0.000 description 19
- -1 nitrate anions Chemical class 0.000 description 17
- 150000002823 nitrates Chemical class 0.000 description 17
- 230000035487 diastolic blood pressure Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 230000009467 reduction Effects 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 11
- 230000037406 food intake Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000024883 vasodilation Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 229960004106 citric acid Drugs 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000009530 blood pressure measurement Methods 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229960005336 magnesium citrate Drugs 0.000 description 5
- 239000004337 magnesium citrate Substances 0.000 description 5
- 235000002538 magnesium citrate Nutrition 0.000 description 5
- 239000000395 magnesium oxide Substances 0.000 description 5
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 5
- 229960000869 magnesium oxide Drugs 0.000 description 5
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 5
- 150000002739 metals Chemical class 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 231100000716 Acceptable daily intake Toxicity 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 235000015191 beet juice Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000009140 magnesium supplementation Methods 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000004317 sodium nitrate Substances 0.000 description 3
- 235000010344 sodium nitrate Nutrition 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 2
- 241000219318 Amaranthus Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 2
- 235000007635 levomefolic acid Nutrition 0.000 description 2
- 239000011578 levomefolic acid Substances 0.000 description 2
- IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Chemical compound [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- YAHRDLICUYEDAU-UHFFFAOYSA-N methylhexaneamine Chemical compound CCC(C)CC(C)N YAHRDLICUYEDAU-UHFFFAOYSA-N 0.000 description 2
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940026510 theanine Drugs 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- AKGJKCZYBKGMIK-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;nitric acid Chemical compound O[N+]([O-])=O.OC(=O)[C@@H](N)CCCNC(N)=N AKGJKCZYBKGMIK-WCCKRBBISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MBSCHHMCRIMBDZ-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;nitric acid Chemical compound O[N+]([O-])=O.NC(=N)N(C)CC(O)=O MBSCHHMCRIMBDZ-UHFFFAOYSA-N 0.000 description 1
- URQMEZRQHLCJKR-UHFFFAOYSA-N 3-Methyl-5-propyl-2-cyclohexen-1-one Chemical compound CCCC1CC(C)=CC(=O)C1 URQMEZRQHLCJKR-UHFFFAOYSA-N 0.000 description 1
- GNAUWRSCHILKCV-UHFFFAOYSA-N 3-nitrooxy-4-(trimethylazaniumyl)butanoate Chemical compound C[N+](C)(C)CC(CC([O-])=O)O[N+]([O-])=O GNAUWRSCHILKCV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 238000010152 Bonferroni least significant difference Methods 0.000 description 1
- 240000008365 Celosia argentea Species 0.000 description 1
- 235000000722 Celosia argentea Nutrition 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020802 Hypertensive crisis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960001983 magnesium aspartate Drugs 0.000 description 1
- 229910001607 magnesium mineral Inorganic materials 0.000 description 1
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 1
- AAJBNRZDTJPMTJ-UHFFFAOYSA-L magnesium;dinitrite Chemical compound [Mg+2].[O-]N=O.[O-]N=O AAJBNRZDTJPMTJ-UHFFFAOYSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- QNIVIMYXGGFTAK-UHFFFAOYSA-N octodrine Chemical compound CC(C)CCCC(C)N QNIVIMYXGGFTAK-UHFFFAOYSA-N 0.000 description 1
- 229960001465 octodrine Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000004304 potassium nitrite Substances 0.000 description 1
- 235000010289 potassium nitrite Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Catalysts (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800361P | 2019-02-01 | 2019-02-01 | |
| US62/800,361 | 2019-02-01 | ||
| US201962866540P | 2019-06-25 | 2019-06-25 | |
| US62/866,540 | 2019-06-25 | ||
| US16/779,349 | 2020-01-31 | ||
| PCT/US2020/016274 WO2020160509A1 (en) | 2019-02-01 | 2020-01-31 | Enhanced nitrate compositions and methods of use |
| US16/779,349 US20200222449A1 (en) | 2019-02-01 | 2020-01-31 | Enhanced Nitrate Compositions and Methods of Use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210119499A KR20210119499A (ko) | 2021-10-05 |
| KR102789451B1 true KR102789451B1 (ko) | 2025-03-31 |
Family
ID=71517286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217027218A Active KR102789451B1 (ko) | 2019-02-01 | 2020-01-31 | 질산염 보강 조성물 및 이의 사용 방법 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20200222449A1 (https=) |
| EP (1) | EP3917543A4 (https=) |
| JP (1) | JP7534310B2 (https=) |
| KR (1) | KR102789451B1 (https=) |
| CN (1) | CN113498345A (https=) |
| AU (2) | AU2020215729B2 (https=) |
| BR (1) | BR112021015110A2 (https=) |
| CA (1) | CA3128232A1 (https=) |
| EA (1) | EA202192132A1 (https=) |
| IL (1) | IL285247A (https=) |
| MX (1) | MX2021009287A (https=) |
| WO (1) | WO2020160509A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8466187B2 (en) | 2007-09-18 | 2013-06-18 | Thermolife International, Llc | Amino acid compositions |
| US12612370B2 (en) | 2011-03-02 | 2026-04-28 | Thermolife International, Llc | Amino acid compositions |
| WO2022192743A1 (en) * | 2021-03-11 | 2022-09-15 | Thermolife International, Llc | Enhanced nitrate, elemental metal, and amino acid compositions and methods of use |
| US11865139B2 (en) | 2020-11-12 | 2024-01-09 | Thermolife International, Llc | Method of treating migraines and headaches |
| WO2022174116A1 (en) * | 2021-02-11 | 2022-08-18 | Thermolife International, Llc | A method of administering nitric oxide gas |
| JP2024541338A (ja) * | 2020-11-12 | 2024-11-08 | サーモライフ インターナショナル， エルエルシー | 血中酸素飽和度を増大させる方法 |
| AU2022220004A1 (en) * | 2021-02-11 | 2023-08-17 | Thermolife International, Llc | A method of administering nitric oxide gas |
| JP2024508952A (ja) * | 2021-03-11 | 2024-02-28 | サーモライフ インターナショナル， エルエルシー | ニトレートと単体金属とアミノ酸との増強された組成物ならびに使用方法 |
| CA3226249A1 (en) * | 2021-08-16 | 2023-02-23 | Thermolife International, Llc | Iron supplement compositions and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180133247A1 (en) * | 2016-11-15 | 2018-05-17 | Berkeley Nox Limited | Novel dietary supplements |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU476799B2 (en) * | 1974-02-04 | 1976-08-05 | Carlton And United Breweries Limited | Preparation of a water soluble isomerised hop extract |
| US6703056B2 (en) * | 2000-09-29 | 2004-03-09 | The Procter + Gamble Co. | Beverage compositions comprising arabinogalactan and defined minerals |
| US7208170B2 (en) * | 2002-09-20 | 2007-04-24 | Petersson Lennart G | Powder teat dip germicide, fungicide and skin conditioner |
| CN100399948C (zh) * | 2002-12-06 | 2008-07-09 | 协和发酵工业株式会社 | 含氨基酸的饮料和减少氨基酸苦味的方法 |
| DK2124638T3 (en) | 2007-02-26 | 2017-03-20 | Heartbeet Ltd | COMPOSITION INCREASING PERFORMANCE AND USING IT |
| US10646508B1 (en) * | 2007-09-18 | 2020-05-12 | Thermolife International, Llc | Method of safely administering nitrate dietary supplements and compositions |
| US7777074B2 (en) | 2007-09-18 | 2010-08-17 | Thermolife International, Llc | Amino acid compounds |
| US20110123654A1 (en) * | 2008-06-06 | 2011-05-26 | Ralf Jaeger | Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon |
| US8303995B1 (en) * | 2008-06-13 | 2012-11-06 | Board Of Regents, The University Of Texas System | Nitrite formulations and their use as nitric oxide prodrugs |
| ES2538652T3 (es) | 2009-06-16 | 2015-06-23 | Dusan Miljkovic | Composiciones y procedimientos para producir un potencial negativo de oxidación-reducción estable en materiales consumibles |
| JP2014513527A (ja) | 2011-04-21 | 2014-06-05 | ネステク ソシエテ アノニム | パフォーマンス向上のための栄養組成物並びにその作製及び使用方法 |
| JP6016610B2 (ja) | 2012-12-20 | 2016-10-26 | 江崎グリコ株式会社 | 筋肉増量用サプリメント |
| CA2965441C (en) * | 2014-10-22 | 2020-03-24 | Innoveco Australia Pty. Ltd. | Process for metal extraction with sorption leaching in wet solids |
| ES2651717B1 (es) | 2016-07-26 | 2018-11-16 | Lara OLLER DUQUE | Solución acuosa cristaloide isotónica |
| WO2020214841A1 (en) * | 2019-04-16 | 2020-10-22 | Thermolife International, Llc | Hexylamine salts and methods of using hexylamine |
-
2020
- 2020-01-31 MX MX2021009287A patent/MX2021009287A/es unknown
- 2020-01-31 EP EP20749283.6A patent/EP3917543A4/en active Pending
- 2020-01-31 AU AU2020215729A patent/AU2020215729B2/en active Active
- 2020-01-31 KR KR1020217027218A patent/KR102789451B1/ko active Active
- 2020-01-31 CA CA3128232A patent/CA3128232A1/en active Pending
- 2020-01-31 EA EA202192132A patent/EA202192132A1/ru unknown
- 2020-01-31 US US16/779,349 patent/US20200222449A1/en active Pending
- 2020-01-31 JP JP2021544571A patent/JP7534310B2/ja active Active
- 2020-01-31 WO PCT/US2020/016274 patent/WO2020160509A1/en not_active Ceased
- 2020-01-31 CN CN202080018208.XA patent/CN113498345A/zh active Pending
- 2020-01-31 BR BR112021015110A patent/BR112021015110A2/pt unknown
-
2021
- 2021-07-29 IL IL285247A patent/IL285247A/en unknown
-
2023
- 2023-06-12 AU AU2023203649A patent/AU2023203649B2/en active Active
- 2023-12-28 US US18/399,677 patent/US20240122969A1/en active Pending
- 2023-12-28 US US18/399,664 patent/US20240122967A1/en active Pending
- 2023-12-28 US US18/399,465 patent/US20240122966A1/en active Pending
- 2023-12-28 US US18/399,668 patent/US20240122968A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180133247A1 (en) * | 2016-11-15 | 2018-05-17 | Berkeley Nox Limited | Novel dietary supplements |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020215729B2 (en) | 2023-03-30 |
| JP2022523513A (ja) | 2022-04-25 |
| EP3917543A4 (en) | 2022-10-12 |
| KR20210119499A (ko) | 2021-10-05 |
| US20200222449A1 (en) | 2020-07-16 |
| US20240122967A1 (en) | 2024-04-18 |
| EA202192132A1 (ru) | 2021-10-19 |
| AU2020215729A1 (en) | 2021-09-02 |
| AU2023203649B2 (en) | 2024-11-14 |
| CA3128232A1 (en) | 2020-08-06 |
| WO2020160509A1 (en) | 2020-08-06 |
| EP3917543A1 (en) | 2021-12-08 |
| US20240122968A1 (en) | 2024-04-18 |
| US20240122966A1 (en) | 2024-04-18 |
| US20240122969A1 (en) | 2024-04-18 |
| MX2021009287A (es) | 2021-11-12 |
| CN113498345A (zh) | 2021-10-12 |
| AU2023203649A1 (en) | 2023-07-06 |
| JP7534310B2 (ja) | 2024-08-14 |
| BR112021015110A2 (pt) | 2022-01-11 |
| IL285247A (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102789451B1 (ko) | 질산염 보강 조성물 및 이의 사용 방법 | |
| Gonzalez et al. | Effects of citrulline supplementation on exercise performance in humans: A review of the current literature | |
| RU2356247C2 (ru) | Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор | |
| JP5762396B2 (ja) | 糖尿病療法の支援のためのα−ケト酸を含有する栄養補助剤 | |
| WO2011075741A1 (en) | Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb) | |
| EP2148580A1 (en) | Compositions and approaches for increasing diet induced thermogenesis, inducing weight loss and maintaining muscles mass and strength | |
| Maheshwari et al. | Latent therapeutic gains of beetroot juice | |
| WO2009082883A1 (fr) | Composition anti-obésité | |
| JP6469283B2 (ja) | アンモニア代謝促進剤 | |
| WO2017206026A1 (zh) | 提升运动能力的能量组合物 | |
| CN112690457A (zh) | 一种用于超重和肥胖人群的营养素组合物配方 | |
| EA049159B1 (ru) | Улучшенный нитратный состав и способы применения | |
| CN116138450A (zh) | 一种含5-氨基乙酰丙酸或其衍生物的运动营养组合物及制备方法和应用 | |
| CN115137066A (zh) | 一种减肥片剂及其制备方法 | |
| WO2007077995A1 (ja) | 筋肉増量剤 | |
| US20250000832A1 (en) | Enhanced nitrate, elemental metal, and amino acid compositions and methods of use | |
| RU2741079C1 (ru) | Пищевая добавка «пребио дкв» | |
| US20250082580A1 (en) | Controlled-release oral formulation and preparation method thereof | |
| WO2026095824A1 (en) | A combination consisting of resveratrol, curcumin, quercetin and nad precursor, a composition comprising the combination and uses thereof | |
| JP2589112B2 (ja) | 酒酔い防止剤 | |
| CN114588207A (zh) | 一种提高运动耐力和促进运动后恢复的组合物及其应用 | |
| CN115721018A (zh) | 一种增强耐力的组合物 | |
| EP3920717A1 (en) | Compositions and methods for the treatment of constipation and other ailments of the gastrointestinal system | |
| HK1123483A (en) | Compositions for weight loss | |
| WO2002069956A2 (en) | Use of carnitine for increasing testosteron |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20210826 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230818 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240806 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20250102 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250327 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250327 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |